We are thrilled to congratulate the WAINUA team from AstraZeneca on being selected as an ELITE100 Marketing Team! Don’t miss a chance to meet them and all of our other incredible ELITE winners tomorrow on June 18th at 230 FIFTH Rooftop in NYC for our celebration of the pharma industry’s best and brightest: https://lnkd.in/g4nE39eW
PM360 Magazine’s Post
More Relevant Posts
-
I help you improve your pipeline because it’s your backbone. ➡️ Success = Sales + Social Selling ✅ Be happy with your strategy; it’s the key to success!
✅ Imagine, every employee generates one lead! Today: 📅 Thursday, August 10th, 2023, at 12pm CET. The employees have more followers than the company. Large companies underestimate the potential! They don't use it for lead generation! What is the reason for that? Marketing and sales are not coordinated! In this event we will show how great the potential is! https://lnkd.in/eCyTbFT4 Enjoy the experience of: Yassin Bader Denes Robert Fantasny Faruk Türk Amir Tahric Flex Flex Precision Plastics Solutions (Switzerland) AG Roche Novartis Novo Nordisk Abbott AstraZeneca GSK Boehringer Ingelheim Sanofi Eli Lilly and Company Johnson & Johnson Merck Group Pfizer Bristol Myers Squibb #medicaldevices #drugdevelopment #drugdelivery
To view or add a comment, sign in
-
-
Future Pharma 2024 is around the corner! Adam Alfi and Mai Shafei are attending the World’s Leading Pharma Commercialization Event. Stay tuned for more insights from the event! #futurepharma2024
To view or add a comment, sign in
-
-
Two weeks ago, over 60 of us came together in NYC for a fantastic day of discussion at the Bioethics International Roundtable as leaders from across the biopharmaceutical industry. As always, the event was inspiring as we explored key topics such as clinical trial diversity, patient centricity, access to medicines globally, and the rapidly evolving focus on ESG in our industry. I was particularly inspired by the discussion focused on sharing individual results to clinical trial participants, a topic that has been a passion for me since my GSK days where I was deeply involved in the development of plain language summaries, internally and externally, as it was a new component of clinical trial transparency spurred on by the EU Clinical Trial Regulation requirement. From that point, it simply made sense to move from sharing aggregate results to sharing individual results. So proud to represent Legacy Health Strategies in this forum and to have developed the capability to operationalize sharing of individual and aggregate results via a digital communication platform connecting sponsors and participants, before, during and after clinical trials. Looking forward to collaborating further to ensure the industry lives up to its full potential for good! - CEO Jessica Scott, MD, JD #BioethicsInternational #BEI #HealthEquity #ClinicalTrials #PatientEngagement #ESG #Transparency #LegacyHealthStrategies #DrugDevelopment #RoundTable #Pharma #NYC
To view or add a comment, sign in
-
-
On both sides of the Atlantic pharma companies are presenting cases to the courts and to national regulators that the innovation cash pipelines will be disrupted, forcing them to either cut back and delay launches or move operations to Asia Pacific or Latin America. Find out more in our newly published whitepaper featuring industry experts: · Christoph Glaetzer, Dipl.Kfm., Chief Global Value and Access at Johnson & Johnson Innovative Medicine · Ricardo Werner Marek, President Europe & Canada at Takeda · Andy Powrie-Smith, Executive Director, Communications & Partnerships at EFPIA - European Federation of Pharmaceutical Industries and Associations Access the full whitepaper here: https://bit.ly/3Vh46Y2
To view or add a comment, sign in
-
-
L.E.K.'s latest Executive Insight with Pierre Jacquet, M.D., Ph.D. Ricardo Brau Anne Dhulesia details a comprehensive analysis of Biopharma M&A trends and implications for Pharma executives and Boards. With over a decade of experience advising clients on Biopharma M&A, our analyses uncovered key trends in the market that may continue to influence deal-making in 2024 and beyond. Importantly, our work closely examined clinical outcomes and commercial performance of historical M&A deals, highlighting key insights for industry decision-makers to consider for transacting deals in today's environment. Given these learnings, we highlight 5 key strategic priorities to successfully navigate the current M&A environment. Link:
To view or add a comment, sign in
-
Following the launch of the Harnessing the Full Potential of Real-World Data Enhance Clinical Trials Roundtable Discussion (12 June 2024, 11am-12pm EST/4pm-5pm BST, 60 minutes), we had the opportunity to sit down with the content director Prishu Kagra to discuss the key themes of the session. Specialists from leading #Pharma organizations Sanofi, Novartis, GSK, AstraZeneca and Parexel will be sharing their best practice use cases for implementing real-world data and evidence to drive innovation, improve patient outcomes, and advance healthcare delivery in clinical trials. Swipe below to see the key themes of the upcoming virtual roundtable >>> Register FREE: https://lnkd.in/eSPseiVg #AMGWorld #Technology #ClinicalOperations #ClinicalInnovation #Digitalization #RealWorldData
To view or add a comment, sign in
-
BMS Decision to Lay Off 2,200 Employees Comes After M&A Spending Spree This week, several Big Pharma companies reported first-quarter 2024 financial results. Biogen beat Wall Street’s profit expectations and reported a spike in the uptake of its Alzheimer’s disease therapy Leqembi, and Novartis raised its 2024 outlook on strong drug sales. Meanwhile Roche’s Q1 sales slipped due to a continued drop in demand for COVID-19 products and the appreciation of the Swiss franc. However, the biggest news of the week was Bristol Myers Squibb’s announcement that it will reduce its headcount by 6%, laying off approximately 2,200 employees, or nearly 30% of all biopharma jobs lost so far in 2024, according to BioWorld. https://lnkd.in/eh8B-JDg
To view or add a comment, sign in
-
Managing Director | Offshore Integrated Pharma Brand Insights - CI, FC, BA & MR | Ex-Novartis | Ex-GSK | Ex-Bayer
It might surprise people that most primary and secondary CI knowledge actually sits in the archives and is often not used in strategy documents (original form) such as IPS (Integrated Product Strategy, a 5-year long-term brand plan) or War Games (scenario plans). At AdametNext, we understand the strategic requirements of marketing teams; hence, our deliverables are always 90 to 100% ready for strategic meetings. This is only possible due to the prior inside-out pharma brand management knowledge we gained while working with the CXO or brand directors.
We are excited to meet our clients and colleagues at the Pharma CI Conference in Munich next month. Feel free to connect with our founder/MD, Virendra Kumar, who will be sharing his learnings from prior experience with leading global pharma companies such as Novartis, GSK, and Bayer.
To view or add a comment, sign in